Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto de Investigacion Sanitaria INCLIVA | OTHER |
| Biobizkaia Health Research Institute | OTHER_GOV |
| Biogipuzkoa Health Research Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.
The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.
The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.
After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.
The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Myotonic Dystrophy Type 1 (DM1) | The group included Individuals with a confirmed genetic diagnosis of Myotonic Dystrophy Type 1 (DM1) |
| |
| Control | The group included control subjects as individuals without a genetic diagnosis of Myotonic Dystrophy Type 1 (DM1). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient Registry | Other | Patient Registry |
|
| Measure | Description | Time Frame |
|---|---|---|
| Genomic Caracterization | Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling. | 1 year, year 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Proteomic Characterization | Biomarker evaluation | 1 year, year 1 |
| WAIS IV neuropsychological tests | IQ, memory, attention, language | 2 years, year 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Participants with Myotonic Dystrophy Type 1 (DM1) will volunteer to participate in this study. The study will be advertised through physician recommendations, outreach and educational activities directed at neuromuscular professionals, the registry website, national and local patient associations, and through patient-focused events, conferences, and scientific meetings across Spain.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gisela Nogales Gadea, Ph.D. | Contact | (+34) 93 554 3050 | gnogales@igtp.cat | |
| Alvaro S Larran Mottino, Ph.D. | Contact | alarran@igtp.cat |
| Name | Affiliation | Role |
|---|---|---|
| Gisela Nogales Gadea, Ph.D. | Germans Trias i Pujol Research Institute | Study Director |
| Arturo Lopez Castel, Ph.D. | INCLIVA Instituto de Investigación Sanitaria | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Andalusia | Spain |
Not provided
| Label | URL |
|---|---|
| DM1-Hub webpage | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009223 | Myotonic Dystrophy |
| ID | Term |
|---|---|
| D009136 | Muscular Dystrophies |
| D020966 | Muscular Disorders, Atrophic |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| Germans Trias i Pujol Hospital |
| OTHER |
| Hospital Infanta Sofia | OTHER |
| Hospital de Basurto | OTHER |
| Hospital Donostia | OTHER |
| Hospitales Universitarios Virgen del Rocío | OTHER |
| Hospital Universitario Marqués de Valdecilla | OTHER |
| Complejo Hospitalario Universitario de Albacete | OTHER |
| Hospital Universitario La Fe | OTHER |
| Hospital Univeritario Ntra. Sra. de la Candelaria | UNKNOWN |
Not provided
Not provided
Not provided
DNA samples
| vHOT | Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed | 1 year, year 1 |
| Muscular Impairment Rating Scale (MIRS) | The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy. Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment. | 1 year, year 1 |
| Hand Grip Strength | Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg). For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis. Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment. | 1 year, year 1 |
| 6MWT | Six-Minute Walk Test | 1 year, year 1 |
| 10MWRT | 10-meter Walk/Run Test | 1 year, year 1 |
| 30CST | 30-Second Chair Stand Test | 1 year, year 1 |
| FVC | Forced Vital Capacity (L) | 1 year, year 1 |
| Electrocardiogram (ECG) | The following ECG-derived parameters and abnormalities are recorded:
All measurements are extracted from the ECG tracing according to standard clinical practice. Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function. | 1 year, year 1 |
| BMI | Body Mass Index | 1 year, year 1 |
| OBGYN events | Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information. | 1 year, year 1 |
| GI symptomatology | Collection of participant-reported gastrointestinal symptoms and related clinical information. | 1 year, year 1 |
| MBS (Myotonia Behaviour Scale) | Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities. The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia: 0: No muscle stiffness
Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia. | 1 year, year 1 |
| Modified Rankin Scale (mRS) | Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities. The scale ranges from 0 to 6, with higher scores indicating greater disability or death: 0: No symptoms
| 1 year, year 1 |
| Patient-Reported Outcome: Quality of life | INQoL (Individualized Neuromuscular Quality of Life Questionnaire) | 1 year, year 1 |
| Patient-Reported Outcome: Fatigue | FSS (Fatigue Severity Scale ) | 1 year, year 1 |
| Patient-Reported Outcome: Dietary Habits | MEDAS-14 (Mediterranean Diet Adherence Screener) | 1 year, year 1 |
| Patient-Reported Outcome: Sleepiness | DSS (Daytime Sleepiness Scale) | 1 year, year 1 |
| Patient-Reported Outcome: Apathy | AES (Apathy Evaluation Scale) | 1 year, year 1 |
| Patient-Reported Outcome: Physical Activity | IPAQ (International Physical Activity Questionnaire) | 1 year, year 1 |
| Patient-Reported Outcome: Mental Health | MHI-5 (Mental Health Inventory) | 1 year, year 1 |
| Virginia Arechavala-Gomeza, Ph.D. |
| IIS Biobizkaia |
| Principal Investigator |
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Basque Country | Spain |
|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Canary Islands | Spain |
|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Cantabria | Spain |
|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Castilla-La Macha | Spain |
|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Catalonia | Spain |
|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Madrid | Spain |
|
| Hospitals within the DM1 network | Recruiting | Multiple Locations | Valencia | Spain |
|
| D020967 | Myotonic Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D009422 | Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |